Self-microemulsion preparation of axitinib

A technology of axitinib and self-microemulsion, applied in the field of medicine, can solve problems such as difficult mixing, excessive uniformity, and high incidence of adverse reactions
CN112618488AActive Publication Date: 2021-04-09HUNAN HUIZE BIO PHARMA CO LTD

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
HUNAN HUIZE BIO PHARMA CO LTD
Publication Date
2021-04-09

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention belongs to the technical field of medicines, and particularly discloses a self-microemulsion preparation of axitinib. The prepared preparation is a self-microemulsion composition and comprises the following components in percentage by mass: 0.1-10% of axitinib, 5-70% of oil phase, 10-90% of a surfactant and 0-50% of a cosurfactant. The dissolution rate and the mixing uniformity of the prepared axitinib preparation meet the requirements, the axitinib preparation is spontaneously dispersed in gastrointestinal fluid under gastrointestinal peristalsis after being orally taken to form O / W type nanoemulsion, and drug molecules are wrapped in a carrier, so that the particle size of the drug molecules is correspondingly increased, the membrane permeation mode is changed after the nanoemulsion is in contact with small intestine epidermal cells, original passive diffusion transport is changed into endocytosis transport, and stimulation of the nanoemulsion to gastrointestinal tracts is reduced through active cytosis or endocytosis absorption, so that stimulation caused by too high local concentration of the medicines and long-time contact with the gastrointestinal walls is reduced, and side effects of the gastrointestinal tracts of the medicines can be reduced.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the technical field of medicine, in particular to a self-microemulsion preparation of axitinib. Background technique

[0002] Axitinib (Axitinib) is a multi-target tyrosine kinase inhibitor developed by Pfizer, which can inhibit vascular endothelial cell growth factor receptors VEGFR1, VEGFR2, VEGFR3, platelet-derived growth factor receptor and c-KIT. It was approved by FDA on January 27, 2012 for advanced kidney cancer that failed other systemic treatments. The currently marketed axitinib products are tablets.

[0003] Axitinib is a white powder with a melting point of 218.4°C. It is slightly soluble in polyethylene glycol 400, slightly soluble in methanol or ethanol, very slightly soluble in acetonitrile, and almost insoluble in water. It is unstable to light, heat, and humidity. prone to degradation. Its solubility in pH 1.2 hydrochloric acid solution at 20°C is 0.8 mg / ml, and in pH 6.8 phosphate buffer solution is 0.2 mi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More